NovaBridge Biosciences (NBP) Preferred Stock Liabilities (2018 - 2019)
NovaBridge Biosciences (NBP) reported Preferred Stock Liabilities of $440.4 million for Q4 2019, up 4.45% year-over-year from $421.6 million in Q4 2018, and up 4.45% quarter-over-quarter from $421.6 million in Q4 2018.
NovaBridge Biosciences (NBP) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Preferred Stock Liabilities data on file, last reported at $440.4 million in Q4 2019.
- Preferred Stock Liabilities for Q4 2019 came in at $440.4 million, up 4.45% year-over-year; the trailing twelve-month figure through Dec 2019 was $440.4 million (up 4.45% YoY), and the FY2019 annual result was $26.2 million, down 93.8% from the prior year.
- Preferred Stock Liabilities grew to $440.4 million in Q4 2019 per NBP's latest filing, from $421.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $440.4 million in Q4 2019 and troughed at $421.6 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 440.42 Mn |
| Dec 31, 2018 | 421.65 Mn |